CDK-inhibitor independent cell cycle progression in an experimental haematopoietic stem cell leukaemia despite unaltered Rb-phosphorylation

被引:0
|
作者
R Huss
S Theis
H J Deeg
机构
[1] Institute of Pathology,Division of Clinical Research, Fred Hutchinson Cancer Research Center and the Department of Medicine
[2] University of Munich,undefined
[3] University of Washington,undefined
来源
British Journal of Cancer | 1999年 / 81卷
关键词
haematopoiesis; CD34; MHC class II; cell cycle; Rb-phosphorylation;
D O I
暂无
中图分类号
学科分类号
摘要
A CD34-negative haematopoietic progenitor cell line, D064, derived from canine bone marrow stromal cells is able to differentiate into haematopoietic progenitors under the influence of growth factor-mediated signalling. While differentiating, these cells eventually start to express MHC class II molecules (DR homologues) on their surface. The stable transfection of the fibroblast-like wild-type cells with retroviral constructs containing the cDNA for the canine MHC class II DR-genes (DRA and DRB) induces a change in morphology, accelerates cell cycle progression and leads to a loss of anchorage-dependent growth. Transfected cells show features of an immature stem cell leukaemia, such as giant cell formation. In wild-type D064 cells the accumulation of the cyclin-dependent kinase inhibitor (cdki) p27kip-1 induces differentiation, which is dependent upon signalling via the ligand for the tyrosine kinase receptor c-kit (stem cell factor). DR-transfected cells instead apparently grow independently of any growth factor-mediated signals and express high levels of the cdkis p27kip-1 and especially p21waf-1/cip-1, concurrently with accelated cell cycle progression. In contrast to the overexpression of cdkis and despite accelerated cell cycle progression, the expression of the G2/M phase transition kinase p34cdc2 is significantly reduced in DR-transfected and transformed cells as compared to the haematopoietic wild-type cell line D064. This might suggest a possible alternative cell cycle progression pathway in this experimental stem cell leukaemia by by-passing the G0/G1 phase arrest, although retinoblastoma (Rb)-phosphorylation remains unaltered. These results provide evidence that mechanisms normally controlling the cell cycle and early haematopoietic differentiation are disrupted by the constitutive transcription and expression of MHC class II genes (DR) leading to a progression and growth of this experimental stem cell leukaemia independent from cell cycle controlling regulators such as p27 and p21.
引用
收藏
页码:808 / 813
页数:5
相关论文
共 50 条
  • [41] Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity - Evidence that mitotic Bcl-2 phosphorylation is JNK-independent
    Du, LH
    Lyle, CS
    Obey, TB
    Gaarde, WA
    Muir, JA
    Bennett, BL
    Chambers, TC
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (12) : 11957 - 11966
  • [42] CCND1-CDK4-mediated cell cycle progression provides a competitive advantage for human hematopoietic stem cells in vivo
    Mende, Nicole
    Kuchen, Erika E.
    Lesche, Mathias
    Grinenko, Tatyana
    Kokkaliaris, Konstantinos D.
    Hanenberg, Helmut
    Lindemann, Dirk
    Dahl, Andreas
    Platz, Alexander
    Hoefer, Thomas
    Calegari, Federico
    Waskow, Claudia
    JOURNAL OF EXPERIMENTAL MEDICINE, 2015, 212 (08): : 1171 - 1183
  • [43] Hyperglycaemia within the first month after allogeneic haematopoietic stem-cell transplantation is an independent risk factor for overall survival in patients with acute myeloid leukaemia
    Aberer, F.
    Kremser, S.
    Mader, J. K.
    Zinke-Cerwenka, W.
    Greinix, H.
    Tripolt, N. J.
    Pieber, T. R.
    Zebisch, A.
    Sill, H.
    Oulhaj, A.
    Sourij, H.
    Woelfler, A.
    DIABETES & METABOLISM, 2017, 43 (06) : 560 - 562
  • [44] HASF, a Novel Paracrine Stem Cell Factor Protein Stimulates Neonatal Cardiomyocyte Cell Cycle Progression Through PI3K-Akt-CDK7 Pathway
    Beigi, Farideh
    Schmeckpeper, Jeffrey
    Pow-anpongkul, Pete
    Payne, J. Alan
    Mu, Hui
    Pratt, Richard E.
    Zhang, Zhiping
    Mirotsou, Maria
    Dzau, Victor J.
    CIRCULATION, 2011, 124 (21)
  • [45] Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F
    Hiyama, H
    Iavarone, A
    Reeves, SA
    ONCOGENE, 1998, 16 (12) : 1513 - 1523
  • [46] Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F
    Hirofumi Hiyama
    Antonio Iavarone
    Steven A Reeves
    Oncogene, 1998, 16 : 1513 - 1523
  • [47] Helicobacter pylori releases a factor(s) inhibiting cell cycle progression of human gastric cell lines by affecting cyclin E/cdk2 kinase activity and Rb protein phosphorylation through enhanced p27KIP1 protein expression
    Sommi, P
    Savio, M
    Stivala, LA
    Scotti, C
    Mignosi, P
    Prosperi, E
    Vannini, V
    Solcia, E
    EXPERIMENTAL CELL RESEARCH, 2002, 281 (01) : 128 - 139
  • [48] Aberrant p16INK4A RNA transcripts expressed in hepatocellular carcinoma cell lines regulate pRb phosphorylation by binding with CDK4, resulting in delayed cell cycle progression
    Cho, JW
    Jeong, YW
    Han, SW
    Park, JB
    Jang, BC
    Baek, WK
    Kwon, TK
    Park, JW
    Kim, SP
    Suh, MH
    Suh, SI
    LIVER INTERNATIONAL, 2003, 23 (03) : 194 - 200
  • [49] Suppression of cell cycle progression by poly(ADP-ribose) polymerase inhibitor PJ34 in neural stem/progenitor cells
    Kurokawa, Suguru
    Okuda, Akiko
    Nishizawa, Yuki
    Furukawa, Kyoko
    Sumihiro, Ayumi
    Nakaji, Yuki
    Tanaka, Seigo
    Takehashi, Masanori
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 510 (01) : 59 - 64
  • [50] Overexpression of Cell Cycle Progression Inhibitor Geminin is Associated with Tumor Stem-Like Phenotype of Triple-Negative Breast Cancer
    Di Bonito, Maurizio
    Cantile, Monica
    Collina, Francesca
    Scognamiglio, Giosue
    Cerrone, Margherita
    La Mantia, Elvira
    Barbato, Antonio
    Liguori, Giuseppina
    Botti, Gerardo
    JOURNAL OF BREAST CANCER, 2012, 15 (02) : 162 - 171